Cytomedix talks Acquisition at Stem Cells USA

At this year’s Stem Cells USA, Ed Field, the Chief Operating Officer of Cytomedix, presented on the acquisition of Aldagen, and how the transaction was mutually beneficial for both parties. Aldagen was about to go the IPO route to raise money, but instead acquired sufficient capital when it was bought by Cytomedix. This deal was made possible for many reasons, but especially benefited because both companies shared a vision for the future of regenerative medicine. Cytomedix now has two commercial products, both of which are expected to generate positive cash flow next year.

-Original content provided by an on-site blogger at the Stem Cells USA & Regenerative Medicine Congress